What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Inve

Jason V. Coloma, Chief Executive Officer of Maze Therapeutics (NASDAQ:MAZE), reported the indirect sale of 27,858 shares of common stock over three open-market transactions on June 22 and June 23, 2026, according to the SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average reported price ($26.04).

What proportion of Coloma's indirect position was affected by this transaction?This sale reduced indirect holdings from 372,867 to 345,009 shares, with no direct ownership shares reported in this filing.

Were the shares sold directly or through trusts, and which entities were involved?All shares sold were held indirectly through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, as disclosed in the filing; no shares were sold from direct ownership.

How does this transaction compare to Coloma's recent trading activity?Since May of 2026, Coloma has made four sell transactions, totaling 69,003 shares sold, with this disposition being the largest single transaction by share count and reflecting a capacity-driven cadence as indirect holdings declined.

What context does the current valuation provide for this sale?The average transaction price was around $26.

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/does-maze-therapeutics-ceos-sale-130601727.html)